multi-kinase inhibitor AIV001

A prolonged-release multi-kinase inhibitor, with potential anti-angiogenic, anti-fibrotic and antineoplastic activities. Upon intradermal or intratumoral administration, AIV001 targets and binds to several kinases, including vascular endothelial growth factor receptor (VEGFR), and inhibits multiple pathways involved in neovascularization, fibrosis, abnormal cell proliferation and inflammation. This may reduce dermal neovascularization and fibroplasia during wound healing and scarring, reduce inflammation and fibrosis associated with certain skin conditions, and may reduce neovascularization and cell proliferation associated with certain types of cancers.